# US 6,730,314 B2 · Culturing encapsulated chondrocytes under reduced oxygen partial pressure to produce cartilage implants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,314 B2
- Document ID: US6730314B2
- Status: Granted
- Kind: B2
- Application number: 09/940,854
- Filed: 2001-08-29
- Published: 2002-05-02
- Granted: 2004-05-04
- Earliest claimed: 2000-08-29
- Assignees: Merck Patent Gesellschaft
- Inventors: Brigitte Jeschke; Jörg Meyer; Peter Adamietz; Norbert Meenen; Christiane Göpfert
- Web page: https://patentgrep.com/patent/US6730314B2

## CPC

- A61L 27/20: Polysaccharides
- A61L 27/3817: {Cartilage-forming cells, e.g. pre-chondrocytes}
- A61L 27/3852: {Cartilage, e.g. meniscus}
- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- A61L 27/52: Hydrogels or hydrocolloids
- C12N 5/0655: {Chondrocytes; Cartilage}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- C12N 2500/38: Vitamins
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A process is provided for the production of a human cartilage implant from chondrocytes cultured in vitro, which come as close as possible to the original with respect to their biochemical composition and biomechanical properties. Up to 20% vol. of human serum is used as medium addition in the process. The chondrocytes can be kept in monolayer culture until the 12th passage in order firstly to be re-differentiated, incubated under a reduced oxygen partial pressure, and subsequently stimulated to form a three-dimensional cartilage tissue due to aggregation under an oxygen partial pressure of 21%. In an embodiment, chondrocytes in alginate beads are cultured in a nutrient solution, which may contain human serum and one or more chondrogenic growth factors, under an oxygen partial pressure of less than 20 volume %, isolated from the alginate beads by a treatment with a chelating agent, aggregated by centrifugation and cultured under an oxygen partial pressure of: −21 volume %.

## Claims

### Claim 1

A method for the production of chondrocyte cells for aggregation, comprising subjecting in vitro cultivated chondrocytes to an alginate phase, comprising: mixing the chondrocytes in an alginate-containing buffer solution, encapsulating the chondrocytes in alginate beads, and cultivating the encapsulated chondrocytes in a nutrient solution comprising one or more chondrogenic growth factors and human serum under an oxygen partial pressure of less than 20 volume %.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said oxygen partial pressure is less than 10 volume %.

### Claim 3

A method for the production of a cartilage implant, comprising:
a) subjecting in vitro cultivated chondrocytes to an alginate phase, comprising: mixing the chondrocytes in an alginate-containing buffer solution, encapsulating the chondrocytes in alginate beads, and cultivating the encapsulated chondrocytes in a nutrient solution under an oxygen partial pressure of less than 20 volume %; and
b) subjecting the chondrocytes from the alginate phase to an aggregation phase, comprising centrifuging chondrocytes, which have been isolated from the alginate by treatment with a chelating agent, thereby forming an aggregate of cells, and cultivating the aggregate of cells under an oxygen partial pressure of 2-21 volume %, in a nutrient solution.

### Claim 4 (depends on 3)

The method of claim 3, wherein the nutrient solution in the alginate phase, the aggregation phase, or both, further comprises human serum, one or more chondrogenic growth factors, or both.

### Claim 5 (depends on 3)

The method of claim 3, wherein the nutrient solution in the alginate phase further comprises human serum, one or more chondrogenic growth factors, or both.

### Claim 6 (depends on 4)

The method of claim 4, wherein the chondrogenic growth factors present in the alginate phase, the aggregate phase, or both, are IGF-1 and TGF-β, in a ratio of 5:10 (w:w).

### Claim 7 (depends on 4)

The method of claim 4, wherein the nutrient solution in the alginate phase, in the aggregate phase, or both, further comprises at least one cytokine.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cytokine is interleukin-4, at a concentration of 0.1 to 3 ng/ml.

### Claim 9 (depends on 5)

The method of claim 5, wherein chondrocytes are centrifuged onto a flat surface whereby the cells form a sheet-like shape.

### Claim 10 (depends on 5)

The method of claim 5, wherein the oxygen partial pressure in the alginate phase is less than 10%.

### Claim 11 (depends on 5)

The method of claim 5, wherein, during the alginate phase, chondrones are formed which have a high ratio of collagen type II to collagen type I.

### Claim 12 (depends on 5)

The method of claim 5, wherein, during the aggregation phase, the nutrient solution comprises up to 20% by volume of human serum.

### Claim 13 (depends on 5)

The method of claim 5, wherein the chondrocytes are human.

### Claim 14 (depends on 13)

The method of claim 13, wherein the chondrocytes are taken from a patient into whom the cartilage implant is to be introduced.

### Claim 15 (depends on 5)

The method of claim 5, further comprising, before the alginate phase, seeding chondrocytes in a cell culture vessel and cultivating them to form a monolayer in a nutrient solution to which human serum and growth factors have been added.

### Claim 16 (depends on 15)

The method of claim 15, wherein the nutrient solution in which cells are cultivated to form a monolayer further comprises at least one cytokine.

### Claim 17 (depends on 16)

The method of claim 16, wherein said at least one cytokine is interleukin-4 at a concentration of 0.1 to 3 ng/ml.

### Claim 18 (depends on 15)

The method of claim 15, wherein the cells are kept in monolayer culture for no more than 12 passages.

### Claim 19 (depends on 15)

The method of claim 15, wherein the cells are kept in monolayer culture for no more than 7 passages.

### Claim 20 (depends on 13)

The method of claim 13, wherein the chondrocytes are taken from a source which is heterologous to the patient into whom the cartilage implant is to be introduced.

### Claim 21 (depends on 4)

A cartilage implant obtained by the method of claim 4.

### Claim 22

A method for the production of a cartilage implant, comprising:
subjecting chondrocytes from an alginate culture to an aggregation phase, comprising centrifuging chondrocytes, which have been isolated from the alginate by treatment with a chelating agent, thereby forming an aggregate of cells, and cultivating the aggregate of cells under an oxygen partial pressure of 2-21 volume %, in a nutrient solution comprising one or more chondrogenic growth factors and human serum, wherein the chondrocytes from the alginate culture have been obtained by mixing the chondrocytes in an alginate-containing buffer solution, encapsulating the chondrocytes in alginate beads, and cultivating the encapsulated chondrocytes in a nutrient solution under an oxygen partial pressure of 0.5 to 20%.

### Claim 23

A method for the production of a human cartilage implant, comprising:
a) subjecting cartilage from a human patient to one or more extracellular matrix digesting enzymes, thereby isolating chondrocytes;
b) seeding the isolated chondrocytes in a cell culture vessel and cultivating said chondrocytes in a nutrient solution to which human serum and growth factors have been added;
c) subjecting the cultivated chondrocytes to an alginate phase, comprising mixing the cells in an alginate-containing buffer solution, encapsulating the chondrocytes in alginate beads, and cultivating the encapsulated cells under an oxygen partial pressure of 0.5 to 20%, at 34-39° C., for 0.5 to 15 weeks, in a nutrient solution comprising one or more chondrogenic growth factors and human serum;
d) isolating the cells from the alginate by treatment with a chelating agent; and
e) subjecting the cells isolated from the alginate to an aggregation phase, comprising centrifuging the isolated cells from the alginate phase onto a flat surface, thereby forming an aggregate of cells, cultivating the centrifuged cells in a nutrient solution comprising one or more chondrogenic growth factors and human serum, re-embedding the aggregate thus formed in an agarose-coated surface, and cultivating the aggregated cells under an oxygen partial pressure of 2-21 volume % in a nutrient solution comprising one or more chondrogenic growth factors and human serum.

### Claim 24

A method for the production of a cartilage implant, comprising:
a) subjecting in vitro cultivated stem cells to an alginate phase, comprising mixing the cells in an alginate-containing buffer solution, encapsulating the chondrocytes in alginate beads, and cultivating the encapsulated under an oxygen partial pressure of 0.5 to 20%, in a nutrient solution comprising one or more chondrogenic growth factors and human serum; and
b) subjecting the encapsulated cells from the alginate phase to an aggregation phase, comprising centrifuging the encapsulated cells from the alginate phase onto a flat surface, thereby forming an aggregate of cells, and cultivating the aggregated cells under an oxygen partial pressure of 2-21 volume % in a nutrient solution comprising one or more chondrogenic growth factors and human serum.
